J.P. Morgan reiterated its buy rating and $55 price target on Pediatrix Medical (PDX) buy rating and $55 price target. The investment bank sees third quarter earnings per share for Pediatrix in the $0.39-$0.40 range versus previous guidance $0.35-$0.37
Analyst Matthew Ripperger says the stock was down just over 14% on Monday, Oct. 8, on no news and that he doesn't think the stock weakness is warranted. He believes it represents an attractive entry point.
Ripperger remains comfortable with $1.26 2001 EPS estimate and his above-consensus $2.30 2002 EPS forecast (which includes $0.65 in non-cash amortization).